Delhi-based healthcare financing startup, LetsMD has raised $1 million a pre-series A funding round led by SRI Capital.
You have read of your 8 free articles this month.
Subscribe to
Medgenera All-Access
Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.
Access articles & resources worth up to US $4, 000 per month.
Register with your email to read the full article.
This article is FREE for you! Unlock the unlimited access by subscribing to Medgenera All-Access.
More in BRIEFING
BRIEFING
First Oral Drug Reducing Risk of Blood Loss in Liver Disease Patients Gets Approved
2016 founded company, Dova Pharma's first drug, Doptelet received US FDA approval as the first oral treatment option to reduce the risk of blood loss in patients with chronic liver disease.
BRIEFING
Melinta Therapeutics Receives CARB-X Funding to Develop New Antibiotics Against Multiple “Superbugs”
No new class of antibiotics has been approved over the last fifty years. Currently, there are 10 new classes of antibiotics in the CARB-X portfolio, if any one of them reaches to patients, it would be the first new class of antibiotic to be approved, since 1962. Melinta Therapeutics funding.
BRIEFING
First CAR-T GeneTherapy for Pediatric Blood Cancer ‘Kymriah’ Now Treats Adult Patients
Novartis' Kymriah has extended the horizon of personalized cancer treatment. It is the only CAR-T therapy that has received FDA approval for two types of cancer indications- non-Hodgkin lymphoma and B-cell ALL.
BRIEFING
First Drug to Treat Polycystic Kidney Disease Bags FDA Approval
First drug treatment- Jynarque (tolvaptan) to slow down the decline in kidney function in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD) received USFDA approval. The drug is developed by Japanese biopharma, Otsuka Pharma.
Most Popular
GROW
7 New Ideas to Start a Healthcare Business in India (2018)
Seven new #healthcare #business ideas in India in 2018. Which one would you prefer to pursue?
NEWLY PUBLISHED
Pharma Patents: Can India Reward Incremental Innovation?
Leave a reply